Review of 1027 patients with newly diagnosed multiple myeloma

被引:1764
作者
Kyle, RA
Gertz, MA
Witzig, TE
Lust, JA
Lacy, MQ
Dispenzieri, A
Fonseca, R
Rajkumar, SV
Offord, JR
Larson, DR
Plevak, ME
Therneau, TM
Greipp, PR
机构
[1] Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Biostat, Rochester, MN 55905 USA
关键词
D O I
10.4065/78.1.21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine the clinical and laboratory features of newly diagnosed multiple myeloma. Patients and Methods: Records of all patients in whom multiple myeloma was initially diagnosed at the Mayo Clinic in Rochester, Minn, from January 1, 1985, to December 31, 1998, were reviewed. Results: Of the 1027 study patients, 2% were younger than 40 years, and 38% were 70 years or older. The median age was 66 years. Anemia was present initially in 73% of patients, hypercalcemia (calcium level 41 mg/dL) in 13%, and a serum creatinine level of 2 mg/dL or more in 19%. The beta(2)-microglobulin level was increased in 75%. Serum protein electrophoresis revealed a localized band in 82% of patients, and immunoelectrophoresis or immunofixation showed a monoclonal protein in 93%. A monoclonal light chain was found in the urine in 78%. Non- secretory myeloma-was recognized in 3% of patients, whereas light-chain myeloma was present in 20%. Conventional radiographs showed an abnormality in 79%. The plasma cell labeling index was 1% or more in 34% of patients. Multivariate analysis revealed that age, plasma cell labeling index, low platelet count, serum albumin value, and,the log of the creatinine value were the most important prognostic factors. Conclusion: The median duration of survival was 33 months and did not improve from 1985 through 1998.
引用
收藏
页码:21 / 33
页数:13
相关论文
共 52 条
[1]  
ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484
[2]   Advances in disease biology: Therapeutic implications [J].
Anderson, KC .
SEMINARS IN HEMATOLOGY, 2001, 38 (02) :6-10
[3]  
[Anonymous], 1973, IOWA SURVEILLANCE EP, P1973
[4]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[5]   Hematopoiesis and cytokines - Relevance to cancer and aging [J].
Baraldi-Junkins, CA ;
Beck, AC ;
Rothstein, G .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2000, 14 (01) :45-+
[6]   Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Desikan, KR ;
Mattox, S ;
Vesole, D ;
Siegel, D ;
Tricot, G ;
Munshi, N ;
Fassas, A ;
Singhal, S ;
Mehta, J ;
Anaissie, E ;
Dhodapkar, D ;
Naucke, S ;
Cromer, J ;
Sawyer, J ;
Epstein, J ;
Spoon, D ;
Ayers, D ;
Cheson, B ;
Crowley, J .
BLOOD, 1999, 93 (01) :55-65
[7]   Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].
Barlogie, B ;
Desikan, R ;
Eddlemon, P ;
Spencer, T ;
Zeldis, J ;
Munshi, N ;
Badros, A ;
Zangari, M ;
Anaissie, E ;
Epstein, J ;
Shaughnessy, J ;
Ayers, D ;
Spoon, D ;
Tricot, G .
BLOOD, 2001, 98 (02) :492-494
[8]   Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients [J].
Berenson, JR ;
Crowley, JJ ;
Grogan, TM ;
Zangmeister, J ;
Briggs, AD ;
Mills, GM ;
Barlogie, B ;
Salmon, SE .
BLOOD, 2002, 99 (09) :3163-3168
[9]   Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, MJ ;
Blacklock, HA ;
Bell, R ;
Simeone, J ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493
[10]   Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated [J].
Blade, J ;
SanMiguel, JF ;
Fontanillas, M ;
Alcala, A ;
Maldonado, J ;
GarciaConde, J ;
Conde, E ;
ConzalezBrito, G ;
Moro, MJ ;
Escudero, ML ;
Trujillo, J ;
Pascual, A ;
Rozman, C ;
Estape, J ;
Montserrat, E .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :2167-2173